United States:
Does Arthrex Matter?
07 September 2021
Winston & Strawn LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Arthrex grabbed headlines, but will it actually be a useful tool
for PTAB oversight? Will the USPTO Director be willing to take a
hard look at PTAB decisions? And what can we expect from a new
Director? Winston & Strawn Attorneys Nimalka Wickramasekera and
Juan Yaquian recently addressed this topic.
Listen to the episode here.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.